| Name | Title | Contact Details |
|---|
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Sterling Life Sciences is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Grabber Performance Group is a Wyoming, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MedAfford Global is a Dallas, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer`s 2009 sales were approximately $4.1 billion. The Company is supported by the efforts of approximately 8,500 employees worldwide.